In this episode of Hims House, Jonathan Stern, Louis Stevens, and Dr. H provide a comprehensive preview of Hims' upcoming Q3 2024 earnings report. They discuss past earnings performance, market reactions, volatility, and expectations for future earnings. Key points include Hims' historical revenue growth, the impact of GLP-1 medications, vertical integrations, and forward-looking projections for the company. The discussion highlights the importance of customer acquisition costs, the value of the new 503B pharmacy, and the anticipation of new product launches. Additionally, the team provides insights into investor sentiment and potential stock price movements post-earnings report. 00:00 Introduction and Overview 00:18 Setting the Stage for Q3 Earnings 00:27 Historical Performance and Market Reactions 03:26 Q2 2024 Recap and Expectations 05:17 Insights from Dr. H on Telehealth and GLP-1 06:44 Hims' Revenue Guidance and Projections 10:47 Discussion on Business Growth and Sustainability 13:37 Product Announcements and Future Roadmap 25:08 503B Pharmacy Acquisition and Vertical Integration 30:13 Earnings Predictions and Stock Price Projections